SANTA CLARA, Calif.--(Business Wire)--
Affymetrix, Inc., (Nasdaq: AFFX) today announced that its Chief Medical Officer,
Dr. Rick Hockett, will address the topic of `Personalized Medicine: Planning for
the Future` at a meeting of the American Association for the Advancement of
Science (AAAS) and the Food and Drug Law Institute (FDLI) on June 1 in
Washington, DC.
Dr. Hockett will speak in a panel discussion at 10:15 AM Eastern time on `State
of the Science: Connecting Biomarkers and Diagnostics.` The panel will be
chaired by Teri Manolio, Director of the Office of Population Genomics, at the
National Institutes of Health. It will also include Leigh Anderson, CEO of the
Plasma Proteome Institute, and David Borsook, Co-Director of the Imaging
Consortium for Drug Development at McLean Hospital, Belmont, MA.
"Identifying biomarkers which increase the benefit-to-risk-ratio for medications
allows doctors to provide more meaningful health outcomes for patients," said
Dr. Hockett. "One of the first examples of personalized medicine began when
doctors utilized glucose measurements to diagnose diabetes and prescribe
insulin. There are still many challenges ahead to developing similarly effective
therapies for more complex diseases such as cancer. I am looking forward to
discussing these and identifying a path forward with such distinguished
colleagues."
Before joining Affymetrix in March of this year, Dr. Hockett served as Medical
Fellow and the Director of Genomic Medicine at Eli Lilly. Earlier he spent seven
years on staff at the University of Alabama at Birmingham Hospital, with the
positions of Assistant Professor of Pathology and Head of Clinical Immunology
and Molecular Diagnostics.
This colloquium is free and open to the public. It will be held at the AAAS
Headquarters, 1200 New York Avenue NW, Washington, DC. For more information
visit: http://www.aaas.org/spp/PM/colloquia
About Affymetrix, Inc.
Affymetrix GeneChip® microarray technology is the industry-standard tool for
analyzing complex genetic information. After inventing microarray technology in
the late 1980s, Affymetrix scientists have been dedicated to developing
innovative products that provide researchers with a more complete view of the
genome. These products continue to accelerate genetic research. They enable
scientists to develop diagnostics which may support the tailoring of treatments
for patients by identifying and measuring the genetic information associated
with complex diseases.
Today, Affymetrix technology is used by the world`s top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading academic,
government, and not-for-profit research institutes. More than 1,800 systems have
been shipped around the world and more than 18,000 peer-reviewed papers have
been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing
facilities in Cleveland, Ohio, and Singapore. The company has about 1,100
employees worldwide and maintains sales and distribution operations across
Europe and Asia. For more information about Affymetrix, please visit the
company`s website at www.affymetrix.com.
Forward-Looking Statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix`
"expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such
statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected, including, but
not limited to: risks of the company`s ability to achieve and sustain higher
levels of revenue, higher gross margins and reduced operating expenses;
uncertainties related to technological approaches, manufacturing and product
development; personnel retention; uncertainties related to cost and pricing of
Affymetrix products; dependence on collaborative partners; uncertainties related
to sole-source suppliers; risks associated with past and future acquisitions;
uncertainties relating to FDA and other regulatory approvals; competition; risks
relating to intellectual property of others and the uncertainties of patent
protection and litigation. These and other risk factors are discussed in
Affymetrix` Form 10-K for the year ended December 31, 2008, and other SEC
reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly
periods. Affymetrix expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in Affymetrix` expectations with regard thereto or
any change in events, conditions or circumstances on which any such statements
are based.
NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks
owned or used by Affymetrix Inc.
Affymetrix Inc.
Media:
Justin O`Kelly, 408-731-5991
Public Relations Manager
or
Investor:
Doug Farrell, 408-731-5285
Vice President, Investor Relations
Copyright Business Wire 2009
